Results

Amarin just rolled out a battery of promising new data for Vascepa — brace yourself for the M&A chatter to come

Amarin hasn’t stopped astonishing analysts.

Five weeks after the company offered a big thumbs-up to its 7-year REDUCE-IT cardio study of Vascepa, with more than 8,000 patients, researchers showed up at the annual science meeting of the AHA with a battery of highly positive results for a slew of secondary endpoints.

But the latest, detailed update also raised a royal ruckus over the weekend over what exactly caused the positive effect, a single significant safety data point to consider and whether the company stacked the deck in its favor with the mineral oil it used in the placebo. And that has the company's shares in the red early Monday.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 33,900+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Scientist, Quality Control
Molecular Templates Austin, TX
Receptionist/Administrative Assistant
Molecular Templates Austin, TX
Principal
Flagship Pioneering Cambridge, MA

Visit Endpoints Careers ->